Anil Thotakura
Head of Immuno-Oncology Orion Pharma
Anil Thotakura, PhD, is Head of Immuno-Oncology at Orion Pharma, Finland, where he leads drug discovery programs targeting cancer immunology. He earned his PhD in Tumour Immunology from Imperial College London and has held key roles in biotech, including pharmacology lead at Kymab (now Sanofi) and Group Leader at Microbiotica, focusing on novel in vivo models to study gut microbiota in cancer and inflammatory diseases.
Seminars
Monday 4th May 2026
Optimising In Vivo Tumour Models for Translational Success: Exploring Strategies to Overcome Preclinical Oncology Modelling Limitations
1:30 pm
- Evaluating in vivo systems for small molecules and immuno-oncology agents, and identifying factors that influence predictive accuracy
- Addressing common pitfalls such as overinterpretation and variability in terminated studies to refine efficacy assessment
- Implementing strategies to improve data relevance, including better understanding of tumour microenvironment and immune interactions
